Global Transthyretin Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Transthyretin market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Transthyretin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Transthyretin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Transthyretin market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Transthyretin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Transthyretin market include Alnylam Pharmaceuticals Inc, Arcturus Therapeutics Inc, Ionis Pharmaceuticals Inc, Neurimmune Holding AG, Prothena Corp Plc, Regeneron Pharmaceuticals Inc and Pfizer Inc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Transthyretin, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Transthyretin, also provides the sales of main regions and countries. Of the upcoming market potential for Transthyretin, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Transthyretin sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Transthyretin market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Transthyretin sales, projected growth trends, production technology, application and end-user industry.
Transthyretin Segment by Company
Alnylam Pharmaceuticals Inc
Arcturus Therapeutics Inc
Ionis Pharmaceuticals Inc
Neurimmune Holding AG
Prothena Corp Plc
Regeneron Pharmaceuticals Inc
Pfizer Inc
Transthyretin Segment by Type
AG-10
Inotersen Sodium
EDE-1307
CRX-1008
ALN-TTRsc02
Others
Transthyretin Segment by Application
Alzheimer's Disease
Familial Amyloid Neuropathies
Cardomyopathy
Neuropathy
Others
Transthyretin Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Transthyretin status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Transthyretin market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Transthyretin significant trends, drivers, influence factors in global and regions.
6. To analyze Transthyretin competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Transthyretin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Transthyretin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Transthyretin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Transthyretin market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Transthyretin industry.
Chapter 3: Detailed analysis of Transthyretin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Transthyretin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Transthyretin in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note:Â Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Transthyretin market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Transthyretin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Transthyretin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Transthyretin market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Transthyretin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Transthyretin market include Alnylam Pharmaceuticals Inc, Arcturus Therapeutics Inc, Ionis Pharmaceuticals Inc, Neurimmune Holding AG, Prothena Corp Plc, Regeneron Pharmaceuticals Inc and Pfizer Inc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Transthyretin, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Transthyretin, also provides the sales of main regions and countries. Of the upcoming market potential for Transthyretin, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Transthyretin sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Transthyretin market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Transthyretin sales, projected growth trends, production technology, application and end-user industry.
Transthyretin Segment by Company
Alnylam Pharmaceuticals Inc
Arcturus Therapeutics Inc
Ionis Pharmaceuticals Inc
Neurimmune Holding AG
Prothena Corp Plc
Regeneron Pharmaceuticals Inc
Pfizer Inc
Transthyretin Segment by Type
AG-10
Inotersen Sodium
EDE-1307
CRX-1008
ALN-TTRsc02
Others
Transthyretin Segment by Application
Alzheimer's Disease
Familial Amyloid Neuropathies
Cardomyopathy
Neuropathy
Others
Transthyretin Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Transthyretin status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Transthyretin market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Transthyretin significant trends, drivers, influence factors in global and regions.
6. To analyze Transthyretin competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Transthyretin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Transthyretin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Transthyretin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Transthyretin market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Transthyretin industry.
Chapter 3: Detailed analysis of Transthyretin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Transthyretin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Transthyretin in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note:Â Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
193 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Transthyretin Sales Value (2020-2031)
- 1.2.2 Global Transthyretin Sales Volume (2020-2031)
- 1.2.3 Global Transthyretin Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Transthyretin Market Dynamics
- 2.1 Transthyretin Industry Trends
- 2.2 Transthyretin Industry Drivers
- 2.3 Transthyretin Industry Opportunities and Challenges
- 2.4 Transthyretin Industry Restraints
- 3 Transthyretin Market by Company
- 3.1 Global Transthyretin Company Revenue Ranking in 2024
- 3.2 Global Transthyretin Revenue by Company (2020-2025)
- 3.3 Global Transthyretin Sales Volume by Company (2020-2025)
- 3.4 Global Transthyretin Average Price by Company (2020-2025)
- 3.5 Global Transthyretin Company Ranking (2023-2025)
- 3.6 Global Transthyretin Company Manufacturing Base and Headquarters
- 3.7 Global Transthyretin Company Product Type and Application
- 3.8 Global Transthyretin Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Transthyretin Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Transthyretin Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Transthyretin Market by Type
- 4.1 Transthyretin Type Introduction
- 4.1.1 AG-10
- 4.1.2 Inotersen Sodium
- 4.1.3 EDE-1307
- 4.1.4 CRX-1008
- 4.1.5 ALN-TTRsc02
- 4.1.6 Others
- 4.2 Global Transthyretin Sales Volume by Type
- 4.2.1 Global Transthyretin Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Transthyretin Sales Volume by Type (2020-2031)
- 4.2.3 Global Transthyretin Sales Volume Share by Type (2020-2031)
- 4.3 Global Transthyretin Sales Value by Type
- 4.3.1 Global Transthyretin Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Transthyretin Sales Value by Type (2020-2031)
- 4.3.3 Global Transthyretin Sales Value Share by Type (2020-2031)
- 5 Transthyretin Market by Application
- 5.1 Transthyretin Application Introduction
- 5.1.1 Alzheimer's Disease
- 5.1.2 Familial Amyloid Neuropathies
- 5.1.3 Cardomyopathy
- 5.1.4 Neuropathy
- 5.1.5 Others
- 5.2 Global Transthyretin Sales Volume by Application
- 5.2.1 Global Transthyretin Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Transthyretin Sales Volume by Application (2020-2031)
- 5.2.3 Global Transthyretin Sales Volume Share by Application (2020-2031)
- 5.3 Global Transthyretin Sales Value by Application
- 5.3.1 Global Transthyretin Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Transthyretin Sales Value by Application (2020-2031)
- 5.3.3 Global Transthyretin Sales Value Share by Application (2020-2031)
- 6 Transthyretin Regional Sales and Value Analysis
- 6.1 Global Transthyretin Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Transthyretin Sales by Region (2020-2031)
- 6.2.1 Global Transthyretin Sales by Region: 2020-2025
- 6.2.2 Global Transthyretin Sales by Region (2026-2031)
- 6.3 Global Transthyretin Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Transthyretin Sales Value by Region (2020-2031)
- 6.4.1 Global Transthyretin Sales Value by Region: 2020-2025
- 6.4.2 Global Transthyretin Sales Value by Region (2026-2031)
- 6.5 Global Transthyretin Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Transthyretin Sales Value (2020-2031)
- 6.6.2 North America Transthyretin Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Transthyretin Sales Value (2020-2031)
- 6.7.2 Europe Transthyretin Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Transthyretin Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Transthyretin Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Transthyretin Sales Value (2020-2031)
- 6.9.2 South America Transthyretin Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Transthyretin Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Transthyretin Sales Value Share by Country, 2024 VS 2031
- 7 Transthyretin Country-level Sales and Value Analysis
- 7.1 Global Transthyretin Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Transthyretin Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Transthyretin Sales by Country (2020-2031)
- 7.3.1 Global Transthyretin Sales by Country (2020-2025)
- 7.3.2 Global Transthyretin Sales by Country (2026-2031)
- 7.4 Global Transthyretin Sales Value by Country (2020-2031)
- 7.4.1 Global Transthyretin Sales Value by Country (2020-2025)
- 7.4.2 Global Transthyretin Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Transthyretin Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Transthyretin Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Transthyretin Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Transthyretin Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Transthyretin Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Transthyretin Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Transthyretin Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Transthyretin Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Transthyretin Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Transthyretin Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Transthyretin Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Transthyretin Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Transthyretin Sales Value Growth Rate (2020-2031)
- 7.9.2 France Transthyretin Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Transthyretin Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Transthyretin Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Transthyretin Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Transthyretin Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Transthyretin Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Transthyretin Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Transthyretin Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Transthyretin Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Transthyretin Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Transthyretin Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Transthyretin Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Transthyretin Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Transthyretin Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Transthyretin Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Transthyretin Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Transthyretin Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Transthyretin Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Transthyretin Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Transthyretin Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Transthyretin Sales Value Growth Rate (2020-2031)
- 7.16.2 China Transthyretin Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Transthyretin Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Transthyretin Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Transthyretin Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Transthyretin Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Transthyretin Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Transthyretin Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Transthyretin Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Transthyretin Sales Value Growth Rate (2020-2031)
- 7.19.2 India Transthyretin Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Transthyretin Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Transthyretin Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Transthyretin Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Transthyretin Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Transthyretin Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Transthyretin Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Transthyretin Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Transthyretin Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Transthyretin Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Transthyretin Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Transthyretin Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Transthyretin Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Transthyretin Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Transthyretin Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Transthyretin Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Transthyretin Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Transthyretin Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Transthyretin Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Transthyretin Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Transthyretin Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Transthyretin Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Transthyretin Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Transthyretin Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Transthyretin Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Transthyretin Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Transthyretin Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Transthyretin Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Transthyretin Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Transthyretin Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Transthyretin Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Transthyretin Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Transthyretin Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Transthyretin Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Transthyretin Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Transthyretin Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Transthyretin Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Transthyretin Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Transthyretin Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Transthyretin Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Transthyretin Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Alnylam Pharmaceuticals Inc
- 8.1.1 Alnylam Pharmaceuticals Inc Comapny Information
- 8.1.2 Alnylam Pharmaceuticals Inc Business Overview
- 8.1.3 Alnylam Pharmaceuticals Inc Transthyretin Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Alnylam Pharmaceuticals Inc Transthyretin Product Portfolio
- 8.1.5 Alnylam Pharmaceuticals Inc Recent Developments
- 8.2 Arcturus Therapeutics Inc
- 8.2.1 Arcturus Therapeutics Inc Comapny Information
- 8.2.2 Arcturus Therapeutics Inc Business Overview
- 8.2.3 Arcturus Therapeutics Inc Transthyretin Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Arcturus Therapeutics Inc Transthyretin Product Portfolio
- 8.2.5 Arcturus Therapeutics Inc Recent Developments
- 8.3 Ionis Pharmaceuticals Inc
- 8.3.1 Ionis Pharmaceuticals Inc Comapny Information
- 8.3.2 Ionis Pharmaceuticals Inc Business Overview
- 8.3.3 Ionis Pharmaceuticals Inc Transthyretin Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Ionis Pharmaceuticals Inc Transthyretin Product Portfolio
- 8.3.5 Ionis Pharmaceuticals Inc Recent Developments
- 8.4 Neurimmune Holding AG
- 8.4.1 Neurimmune Holding AG Comapny Information
- 8.4.2 Neurimmune Holding AG Business Overview
- 8.4.3 Neurimmune Holding AG Transthyretin Sales, Value and Gross Margin (2020-2025)
- 8.4.4 Neurimmune Holding AG Transthyretin Product Portfolio
- 8.4.5 Neurimmune Holding AG Recent Developments
- 8.5 Prothena Corp Plc
- 8.5.1 Prothena Corp Plc Comapny Information
- 8.5.2 Prothena Corp Plc Business Overview
- 8.5.3 Prothena Corp Plc Transthyretin Sales, Value and Gross Margin (2020-2025)
- 8.5.4 Prothena Corp Plc Transthyretin Product Portfolio
- 8.5.5 Prothena Corp Plc Recent Developments
- 8.6 Regeneron Pharmaceuticals Inc
- 8.6.1 Regeneron Pharmaceuticals Inc Comapny Information
- 8.6.2 Regeneron Pharmaceuticals Inc Business Overview
- 8.6.3 Regeneron Pharmaceuticals Inc Transthyretin Sales, Value and Gross Margin (2020-2025)
- 8.6.4 Regeneron Pharmaceuticals Inc Transthyretin Product Portfolio
- 8.6.5 Regeneron Pharmaceuticals Inc Recent Developments
- 8.7 Pfizer Inc
- 8.7.1 Pfizer Inc Comapny Information
- 8.7.2 Pfizer Inc Business Overview
- 8.7.3 Pfizer Inc Transthyretin Sales, Value and Gross Margin (2020-2025)
- 8.7.4 Pfizer Inc Transthyretin Product Portfolio
- 8.7.5 Pfizer Inc Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Transthyretin Value Chain Analysis
- 9.1.1 Transthyretin Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Transthyretin Sales Mode & Process
- 9.2 Transthyretin Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Transthyretin Distributors
- 9.2.3 Transthyretin Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.


